BioDrugs Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence Ira Jacobs*, Reginald Ewesuedo, Sadiq Lula, Charles Zacharchuk

*Corresponding author: Ira Jacobs; Pfizer Essential Health, Pfizer Inc, 235 East 42nd Street, New York, NY, 10017-5755, USA.

Email: ira.jacobs@pfizer.com

Supplementary Table S7. Leading 10 journals publishing on biosimilars in oncology (2002–2015)

	Year							
Journal (total records, all years) ^a	2005	2009	2010	2011	2012	2013	2014	2015
mAbs (n = 7)	0	0	0	1	1	2	0	3
Targeted Oncology $(n = 3)$	0	0	0	0	3	0	0	0
Seminars in Oncology $(n = 3)$	0	0	0	0	0	2	1	0
Journal of the National Comprehensive Cancer Network $(n = 2)$	0	0	0	2	0	0	0	0
Blood $(n = 2)$	0	0	0	1	1	0	0	0
Leukemia and Lymphoma $(n = 2)$	0	1	0	0	0	0	1	0
Oncologie $(n = 2)$	1	0	0	1	0	0	0	0
Electrophoresis $(n = 2)$	0	0	0	0	0	1	1	0
BioDrugs $(n = 2)$	0	0	0	0	0	1	1	0
Expert Review of Anticancer Therapy (n = 2)	0	0	0	0	0	0	0	2
Annals of Oncology $(n = 2)$	0	0	0	0	0	2	0	0
Future Oncology $(n = 2)$	0	0	1	0	0	0	0	1
Grand total	1	1	1	5	5	8	4	6

^a Publishing on biosimilars in the field of oncology.